XML 40 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration and Licensing Agreements (Tables)
12 Months Ended
Dec. 31, 2018
Collaboration and Licensing Agreements  
Schedule of revenue by licensees

The $40.6 million, $46.2 million and $109.0 million of revenue recorded for the years ended December 31, 2018, 2017 and 2016, respectively, was earned principally from the following licensees (in millions):

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

 

 

December 31, 

 

 

 

2018

 

2017

 

2016

 

 

 

 

 

(As Revised)

 

(As Revised)

 

Amgen

    

$

0.6

    

$

10.0

    

$

31.2

 

Alexion

 

 

20.0

 

 

 —

 

 

5.0

 

CSL

 

 

 —

 

 

3.5

 

 

 —

 

MorphoSys

 

 

 —

 

 

12.5

 

 

 —

 

Novo Nordisk

 

 

 —

 

 

 —

 

 

2.7

 

Novartis

 

 

20.0

 

 

20.1

 

 

69.9

 

Other

 

 

 —

 

 

0.1

 

 

0.2

 

Total

 

$

40.6

 

$

46.2

 

$

109.0

 

 

Schedule of disaggregation of revenue

The below table summarizes the disaggregation of revenue recorded for the years ended December 31, 2018, 2017 and 2016 (in millions):

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

 

December 31, 

 

 

2018

 

2017

 

2016

 

 

 

 

(As Revised)

 

(As Revised)

Research collaboration

    

$

20.1

    

$

20.1

    

$

34.2

Milestone

 

 

20.5

 

 

26.0

 

 

5.0

Licensing

 

 

 —

 

 

0.1

 

 

69.8

Total

 

$

40.6

 

$

46.2

 

$

109.0

 

Schedule of revenue from U.S. and Non U.S. sources

A breakdown of our revenue from U.S. and Non‑U.S. sources for the years ended December 31, 2018, 2017 and 2016 is as follows (in millions):

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

 

 

December 31, 

 

 

 

2018

 

2017

 

2016

 

 

 

 

 

 

(As Revised)

 

(As Revised)

 

U.S. Revenue

    

$

40.6

    

$

30.2

    

$

106.3

 

Non-U.S. Revenue

 

 

 —

 

 

16.0

 

 

2.7

 

Total

 

$

40.6

 

$

46.2

 

$

109.0